Baiquan Biology completed over 200 million yuan in Series A financing.

36Kr learned that recently, "Baiquan Biotech" announced the completion of over 200 million yuan in Series A financing. This round of financing was led by Longpan Investment, followed by Shanghai Science and Technology Innovation Fund and Pudong Venture Capital. Existing shareholders Shanghai Industrial Capital and Kaifeng Venture Capital continued to increase their investments. The funds from this financing will be mainly used to accelerate the process of registration and clinical trials of the company's core product - the world's first anti - tumor drug targeting the CD3L1 target, and simultaneously promote the R & D layout of multiple new - target tumor treatment pipelines.